Emicizumab is well tolerated and effective in people with congenital haemophila A regardless of age severity of disease or inhibitor status a scoping review
Date
Journal Title
Journal ISSN
Volume Title
Publisher
WILEY-BLACKWELL
Abstract
Description
Keywords
Citation
WOS